ContractPharmaceutical Product Co-Development and License Agreement • December 23rd, 2015 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission
AMENDMENT No. 1 To PHARMACEUTICAL PRODUCT CO-DEVELOPMENT AND LICENSE AGREEMENTPharmaceutical Product Co-Development and License Agreement • December 23rd, 2015 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT No. 1 TO THE PHARMACEUTICAL PRODUCT CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”), effective as of March ___, 2014 (the “Amendment No. 1 Effective Date”), is made by and between Cancer Prevention Pharmaceuticals, Inc., (“CPP”) and Tillotts Pharma AG, (“TILLOTTS”).
